Predictable First Patient In. Across Every Jurisdiction.
Trial Activation Intelligence (TAI) compresses activation from 120 days to 30-45. Your trials start faster, your burn rate drops, patients get access.
The Math That Keeps Clinical Operations Up at Night
Phase III direct costs
enrollment burn
average activation
Protocol In → First Patient In
Protocol Intelligence
Your protocol parsed into structured regulatory requirements within hours
Jurisdiction Mapping
Simultaneous jurisdiction mapping — one protocol launches across FDA, ANVISA, CDSCO. EU CTR, NMPA, and additional jurisdictions in development.
Site Validation
Site readiness validated before you commit budget
Audit-Ready Activation
Audit-ready packets submitted — lineage preserved, First Patient In predicted with confidence bands
activation compression
first-submission approval
“Sponsors require predictability, not dashboards.”
Works With Your Existing Stack
Integrates with Veeva, Medidata, existing CTMS via API-first architecture
Plugin boundary: we orchestrate, your systems govern. We never store a document, never capture a data point.
Human-in-the-loop by design — Celina recommends, your team decides
Frequently Asked Questions
How long does it take to deploy TAI for a new trial?
Initial pilot deployment typically takes 4-6 weeks, including protocol configuration, jurisdiction mapping, and site readiness calibration. Subsequent trials on the same jurisdictions activate faster as the Country Blueprints are already encoded.
What does a clinical trial delay cost per day?
Clinical trial activation delays cost sponsors approximately $55,000 per day in direct costs, with enrollment burn rates of $600,000 to $1.2 million per month while sites remain inactive.
How does Celina integrate with our existing CTMS?
Celina integrates via API-first architecture with Veeva, Medidata, and existing CTMS platforms. Plugin boundary: we orchestrate activation workflows, your systems govern storage. No rip-and-replace required.
Does Celina make regulatory decisions?
No. Celina generates audit-ready regulatory packets and validates them against jurisdiction-specific requirements. All regulatory and clinical decisions remain with your team. Human-in-the-loop is architecture, not just governance.
Can TAI support multi-country trial launches?
Yes. TAI supports simultaneous activation across FDA, ANVISA, and CDSCO jurisdictions. One protocol can activate in parallel across the US, Brazil, and India with jurisdiction-specific documentation generated for each.
See how TAI compresses your next trial activation.
Presenting at DIA 2026 · Philadelphia · June 14-18